Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29004413 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL937530 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL29004411 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2532389 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL939851 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL1679410 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2533366 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2535103 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL10247600 | 1.00 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2531537 | 1.00 | TBXAS1 (1.00) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230378532-A1 | PolyElectrolyte Composition and Methods of Preparation Thereof | Kraton Corporation (US) | 2023-11-23 | — | — | US | claimed |
| EP-4280332-A1 | POLYELECTROLYTE COMPOSITION AND METHODS OF PREPARATION THEREOF | Kraton Polymers Nederland B.V. (NL) | 2023-11-22 | — | — | EP | claimed |
| CN-117080543-A | Polyelectrolyte composition and preparation method thereof | 科腾聚合物荷兰有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | claimed |
| EP-3883522-B1 | USE OF A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE FOR REDUCING THE STICKINESS OF A DENTAL IMPRESSION COMPOSITION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-08-29 | — | — | US | disclosed |
| EP-4346741-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230378532-A1 | PolyElectrolyte Composition and Methods of Preparation Thereof | Kraton Corporation (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4280332-A1 | POLYELECTROLYTE COMPOSITION AND METHODS OF PREPARATION THEREOF | Kraton Polymers Nederland B.V. (NL) | 2023-11-22 | — | — | EP | disclosed |
| CN-117080543-A | Polyelectrolyte composition and preparation method thereof | 科腾聚合物荷兰有限责任公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022248954-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-3883522-A1 | CURABLE COMPOSITION CONTAINING A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE | 3M Innovative Properties Company (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-7943650-B2 | Methods of treating cancer with imidazolyl compounds | OSTA BIOTECHNOLOGIES (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| EP-0110429-B1 | RETARDERS FOR THE POLYMERISATION OF AZIRIDINE COMPOUNDS | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | disclosed |
| EP-0110429-A2 | Retarders for the polymerisation of aziridine compounds | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | TBXAS1 469/4885 |
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | INTS9, PUF60, TAS2R42 | TBXAS1 3950/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | TBXAS1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.